Log in

Relevant bibliographies by topics / Mifamurtide / Journal articles

Journal articles on the topic 'Mifamurtide'

To see the other types of publications on this topic, follow the link: Mifamurtide.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Mifamurtide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tacyildiz, Nurdan, Sonay incesoy Ozdemir, Emel Cabi Unal, Handan Dincaslan, Gulsan Yavuz, Fikret Asarcikli, Gulsah Tanyildiz, and Yusuf Yildiz. "Efficiency and toxicity of mifamurtid in childhood osteosarcoma." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e22010-e22010. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e22010.

Full text

Abstract:

e22010 Background: There are only few data concerning efficiency and toxicity of mifamurtide in children with osteosarcoma (OS). The aim of this study was to evaluate efficiency and side effects of mifamurtide in childhood OS. Methods: We retrospectively analyzed the data of 18 patients with OS and who received mifamurtide between January 2012 and December 2016. Four hundred seventy seven doses of 2 mg/m2intravenous mifamurtide, along with paracetamol premedication were given in 15 patients with primary non-metastatic OS after complete surgical resection and 3 patients with progressive OS. Results: There were 11 males and 7 females, and the median age was 14 years (ranged, 9-18). The median follow-up time was 20 months (ranged, 7-51). The metaphyseal plates around the knee was the most frequent disease location with 94.4%. The median necrosis percentage was 94 (range, 35-100). All patients received Euromos protocol. The most common side effects were chills and fever (17/18). These reactions were observed in 4 patients during every administration, in only one patient at last administration and in the remaining 12 patients during first or first two administration. Headache, myalgia and arthralgia were observed in 2 patients during every infusion. In another one case, headache was observed during only first two infusions and he also hearing loss was developed (could be related CisPlatin) Back pain was observed in two patient during first infusion but one them suffered with severe back pain after few doses and stoped Mifamurtid. . Grade 3-4 neutropenia, trombocytopenia, abnormal liver enzymes and abnormal BUN and creatinin levels were not observed in patients who received mifamurtide alone after completion of chemotherapy. Of the 15 patients with primary non-metastatic OS treated with the addition of mifamurtide to chemotherapy, 13 showed complet remission for median 24 months (ranged,16-36) and 2 patients are still under treatment with complet remission. Of the 3 patients with progressive disease, 2 died and 1 had progressive disease for 51 months. Conclusions: Mifamurtide therapy is safe and well tolerated in childhood OS. Chills and fever were the major side effects, These events were transient and often no longer observed in subsequent administrations.

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Mifamurtide." Drugs in R & D 9, no. 2 (2008): 131–35. http://dx.doi.org/10.2165/00126839-200809020-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Frampton, James E. "Mifamurtide." Pediatric Drugs 12, no. 3 (June 2010): 141–53. http://dx.doi.org/10.2165/11204910-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nastasi, Nicoletta, Angela Subbiani, Maria Letizia Taddei, Lucia Scala, Angela Tamburini, Claudio Favre, and Maura Calvani. "Abstract 2007: Use of an anti-IL-10 antibody to improve Mifamurtide efficacy on aggressive osteosarcoma cells." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2007. http://dx.doi.org/10.1158/1538-7445.am2022-2007.

Full text

Abstract:

Abstract Osteosarcoma is a primary malignant bone tumor highly aggressive and metastasizing, composed of mesenchymal cells producing osteoid and immature matrix. Osteosarcoma is the most frequent bone tumor and it mainly affects children and adolescents. The main treatment option is a combination of surgery and chemotherapy. Research into new therapeutic strategies to improve the quality of life of patients is currently underway. The development of the anti-tumor immunostimulant drug Mifamurtide is part of this research. There are very conflicting opinions on the therapeutic validity of this drug. Therefore, we tested experimentally the effectiveness of Mifamurtide in three cell lines of osteosarcoma (MG-63, HOS, 143B) with different grades of malignancy, grown in co-culture with macrophage to allow the correct internalization of the drug. Through in vitro experiments, we analyzed the effects of Mifamurtide on tumor cell viability, on cellular signaling pathway and on macrophage polarization. Results show that Mifamurtide loses its effectiveness as the tumor malignity increases. The most aggressive tumor cells are not affected by the therapy, probably because they implement methods of resistance to apoptosis. Furthermore, they would be able to affect the tumor microenvironment to their own advantage. To better understand Mifamurtide impact on tumor microenvironment, we also performed a cytokine assay on the culture medium in which the cells grew. The most significant results were identified in the interleukine-10 (IL-10): IL-10 is expressed in higher quantities in the highest-grade osteosarcoma cells. This anti-inflammatory cytokine can inhibit the synthesis of pro-inflammatory cytokine and suppresses the antigen presentation capacity of APC cells. This allows cancer cells to evade immune surveillance mechanisms. In vivo and in vitro results show that the synergic use of an anti-IL-10 antibody in combination with Mifamurtide can improve its efficacy. Here, we provide experimental evidence that the addition of an anti-IL-10 antibody to Mifamurtide causes a significant death rate in more aggressive osteosarcoma cells and lower metastasis, compared to Mifamurtide only. In conclusion, considering our data, it could be proposed a new treatment protocol for metastatic osteosarcoma that includes the use of an anti-IL10 antibody integrated with the administration of Mifamurtide to increase its effectiveness in this clinical context. Citation Format: Nicoletta Nastasi, Angela Subbiani, Maria Letizia Taddei, Lucia Scala, Angela Tamburini, Claudio Favre, Maura Calvani. Use of an anti-IL-10 antibody to improve Mifamurtide efficacy on aggressive osteosarcoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2007.

APA, Harvard, Vancouver, ISO, and other styles

5

Brard, Caroline, Sophie Piperno-Neumann, Jessy Delaye, Laurence Brugières, Lisa V. Hampson, Gwénaël Le Teuff, Marie-Cécile Le Deley, and Nathalie Gaspar. "Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma." BMJ Open 9, no. 5 (May 2019): e025877. http://dx.doi.org/10.1136/bmjopen-2018-025877.

Full text

Abstract:

IntroductionThe controversial results on the mifamurtide efficacy associated with chemotherapy, issued from the American INT-0133-study, in localised osteosarcomas, and the underpowered analysis performed separately in metastatic patients, should be clarified to homogenise international use of this promising drug. The European Commission has granted a marketing authorisation to mifamurtide combined with postoperative chemotherapy in localised osteosarcomas but not in metastatic patients, while the Food and Drug Administration (FDA) has denied this authorisation.Methods and analysisSarcome-13/OS2016 trial is a multicentre randomised open-label phase II trial evaluating the survival benefit of mifamurtide administered during 36 weeks in combination with postoperative chemotherapy versus chemotherapy alone, in patients >2 and ≤50 years with newly diagnosed high-risk localised or metastatic osteosarcoma. The main objective is to evaluate the impact on event-free survival (EFS) of mifamurtide on intention-to-treat population. The secondary objectives are to evaluate the impact of mifamurtide on overall survival, to evaluate the feasibility and toxicity of the planned treatment, to correlate biology/immunology with the mifamurtide efficacy/toxicity. With a total of 126 enrolled patients and 51 events, the power is 80% if mifamurtide is associated with an 18% improvement of the 3-year EFS (52%vs70%, equivalent to an HR=0.55), with a one-sided logrank test alpha=10%. As relevant historical data are available (aggregate treatment effect from the INT-0133 trial and individual data from the control group of the Sarcome-09/OS2006 trial), a Bayesian analysis is also planned.Ethics and disseminationThis study was approved by the ‘Comité de Protection des Personnes Ile de France I’ (12/06/2018), complies with the Declaration of Helsinki and French laws and regulations, and follows the International Conference on Harmonisation E6 Guideline for Good Clinical Practice. The trial results, even if they are inconclusive, as well as biological ancillary studies will be presented at appropriate international congresses and published in international peer-review journals.Trial registration numberEudraCT 2017-001165-24,NCT03643133

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Mifamurtide boosts chemo efficacy in osteosarcoma." Inpharma Weekly &NA;, no. 1626 (February 2008): 7. http://dx.doi.org/10.2165/00128413-200816260-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Mifamurtide receives positive opinion in Europe." Inpharma Weekly &NA;, no. 1666 (November 2008): 22. http://dx.doi.org/10.2165/00128413-200816660-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Anderson, P. M., M. Tomaras, and K. McConnell. "Mifamurtide in osteosarcoma - A practical review." Drugs of Today 46, no. 5 (2010): 327. http://dx.doi.org/10.1358/dot.2010.46.5.1500076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ando, Kosei, Kanji Mori, Nedège Corradini, Françoise Redini, and Dominique Heymann. "Mifamurtide for the treatment of nonmetastatic osteosarcoma." Expert Opinion on Pharmacotherapy 12, no. 2 (January 13, 2011): 285–92. http://dx.doi.org/10.1517/14656566.2011.543129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Meyers, Paul A. "Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma." Expert Review of Anticancer Therapy 9, no. 8 (August 2009): 1035–49. http://dx.doi.org/10.1586/era.09.69.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Tacyildiz, Nurdan, Sonay Incesoy Ozdemir, Emel Unal, Melda Berber, Handan Dincaslan, and Gulsan Yavuz. "The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma." Journal of Pediatric Hematology/Oncology 40, no. 6 (August 2018): e373-e376. http://dx.doi.org/10.1097/mph.0000000000001236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Şimşek, Meral, Erman Ataş, Emin Ümit Bağrıaçık, Armağan Günal, and Bülent Ünay. "Type 4 hypersensitivity development in a case due to mifamurtide." Turkish Journal of Pediatrics 62, no. 4 (2020): 694. http://dx.doi.org/10.24953/turkjped.2020.04.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Li, Yuexian, Mihaela Plesescu, and Shimoga R. Prakash. "Synthesis of isotopically labeled versions ofL-MTP-PE (mifamurtide) and MDP." Journal of Labelled Compounds and Radiopharmaceuticals 56, no. 9-10 (July 2013): 475–79. http://dx.doi.org/10.1002/jlcr.3078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Venkatakrishnan, K., P. Meyers, D. R. Mould, B. Green, T. W. Synold, C. Oliva, and P. Anderson. "9428 POSTER Pharmacokinetics and Pharmacodynamics of Liposomal Mifamurtide in Patients With Osteosarcoma." European Journal of Cancer 47 (September 2011): S671. http://dx.doi.org/10.1016/s0959-8049(11)72572-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Jimmy, Rincy, Cindy Stern, Karolina Lisy, and Sarahlouise White. "Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma." JBI Database of Systematic Reviews and Implementation Reports 15, no. 8 (August 2017): 2113–52. http://dx.doi.org/10.11124/jbisrir-2016-003105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Palmerini, Emanuela, Catalina Marquez, Cristina Meazza, Angela Tamburini, Gianni Bisogno, Francisco José Bautista Sirvent, Virginia Ferraresi, et al. "ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastaticextremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 11527. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.11527.

Full text

Abstract:

11527 Background: Overexpression of ABCB1/P-glycoprotein (Pgp) predicts poor outcome in retrospective osteosarcoma series.Two prospective trials with Pgp expression and post-induction histologic response as stratification factors were activated in Italy (ISG/OS-2) and Spain (GEIS-33). Methods: Patients ≤ 40 years with extremity non-metastatic high-grade osteosarcoma were eligible. Analysisi of Pgp expression from diagnostic biopsy was centralized. Preoperatively, all patients received methotrexate, adriamycin, cisplatinum (MAP). Surgery was performed at week 8. All patients received a dose of adriamycin following surgery. In case of Pgp overexpression (Pgp+), mifamurtide (2 mg/m2 twice/week for 3 months then weekly for 6 months) was added after surgery, with 4 consecutive cycles of ifosfamide 3 gr/m2/day, day 1-5 (HDIFO) in case of poor histologic response (necrosis < 90%) to MAP. Patients without overexpression of Pgp (Pgp-) received MAP postoperatively, regardless the pathological response. From March 2013, an amendment increased high dose methotrexate cumulative dose from 60 g/m2 (5 cycles) to 120 mg/m2 (10 cycles). The post-amendment regimen was adopted in the observational prospective study by GEIS. Here we present the merged analysis of ISG/OS-2 patients treated post-amendment and GEIS-33. Results: From March 2013 to April 2018, 274 patients were included. Median age was 14 years (range 4-38), male/female: 163/111; 90 were Pgp-, 164 were Pgp+, 20 not evaluable. With a median follow-up of 48 months (1.3-78.5 months), the 3-year EFS and OS were 71.9% (95%CI 66-76.9) and 88% (95%CI: 83.2-91.5) respectively, with no inferior survival for Pgp positive patients and improved survival for good responders (Table). Conclusions: In this prospective uncontrolled study with a risk-adapted strategy for non-metastatic osteosarcoma, survival is superior to that of all ISG/GEIS previous series. The 3-year EFS of 71.9% compares favorably with other reports. Pgp+ patients performed well in this study, in which mifamurtide and HDIFO were added after a poor response to MAP. Clinical trial information: NCT01459484; NCT04383288. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Mifamurtide* [L-MTP-PE] has displayed encouraging activity in patients with advanced osteosarcoma." Inpharma Weekly &NA;, no. 1639 (May 2008): 7. http://dx.doi.org/10.2165/00128413-200816390-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Punzo, Francesca, Giulia Bellini, Chiara Tortora, Daniela Di Pinto, Maura Argenziano, Elvira Pota, Alessandra Di Paola, Martina Di Martino, and Francesca Rossi. "Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells." Oncotarget 11, no. 7 (February 18, 2020): 687–98. http://dx.doi.org/10.18632/oncotarget.27479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bekçioğlu, Ömer, Safiye Aktas, Melek Aydın, and Nur Olgun. "The Effect of Ifosfamide and Mifamurtide Loaded Cement on The Viability of Osteosarcoma Cells." Turkish Journal of Hip Surgery 1, no. 3 (2021): 90–95. http://dx.doi.org/10.5505/tjhs.2021.76486.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Johal, Sukhvinder, Stephen Ralston, and Christopher Knight. "Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness Analysis." Value in Health 16, no. 8 (December 2013): 1123–32. http://dx.doi.org/10.1016/j.jval.2013.08.2294.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Brosa, M., del Muro X. García, J. Mora, A. Villacampa, T. Pozo, C. Adán, M. Grande, E. García, and L. Cubells. "Economic Considerations On the Use of Mifamurtide In the Treatment of Osteosarcoma In Spain." Value in Health 17, no. 7 (November 2014): A526—A527. http://dx.doi.org/10.1016/j.jval.2014.08.1662.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Monge, Claire, Camille Ayad, Anne-Lise Paris, Renaud Rovera, Evelyne Colomb, and Bernard Verrier. "Mucosal Adjuvants Delivered by a Mucoadhesive Patch for Sublingual Administration of Subunit Vaccines." International Journal of Molecular Sciences 23, no. 21 (November 3, 2022): 13440. http://dx.doi.org/10.3390/ijms232113440.

Full text

Abstract:

Among mucosal administration routes for vaccines, the sublingual route has been proven capable of inducing a potent systemic and mucosal immune response. However, the absence of a simple and compliant delivery system and the lack of robust mucosal adjuvants impede the development of sublingual vaccines. Here, we describe a mucoadhesive patch made of a layer-by-layer assembly of polysaccharides, chitosan, and hyaluronic acid. The mucoadhesive patch was covered by adjuvanted nanoparticles carrying viral proteins. We showed that the nanoparticles effectively cross the outer layers of the sublingual mucosa to reach the epithelium. Furthermore, the encapsulated adjuvants, 3M-052 and mifamurtide, targeting toll-like receptor (TLR) 7/8 and nucleotide-binding oligomerization domain-2 (NOD2), respectively, remain fully active after encapsulation into nanoparticles and exhibit a cytokine/chemokine signature similar to the mucosal gold-standard adjuvant, the cholera toxin. However, the particulate adjuvants induced more moderate levels of proinflammatory interleukin (IL)-6 and keratinocyte chemoattractant (KC), suggesting a controlled activation of the innate immune response.

APA, Harvard, Vancouver, ISO, and other styles

23

Múdry, Peter, Michal Kýr, Ondřej Rohleder, Michal Mahdal, Iva Staniczková Zambo, Marta Ježová, Tomáš Tomáš, and Jaroslav Štěrba. "Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis." Journal of Bone Oncology 28 (June 2021): 100362. http://dx.doi.org/10.1016/j.jbo.2021.100362.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Venkatakrishnan, Karthik, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede, Thomas Marbury, Kambiz Farbakhsh, Cristina Oliva, and Ashley Milton. "Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment." British Journal of Clinical Pharmacology 77, no. 6 (May 22, 2014): 986–97. http://dx.doi.org/10.1111/bcp.12260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Venkatakrishnan, Karthik, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede, Thomas Marbury, Kambiz Farbakhsh, Cristina Oliva, and Ashley Milton. "Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment." British Journal of Clinical Pharmacology 77, no. 6 (May 22, 2014): 998–1010. http://dx.doi.org/10.1111/bcp.12261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Additional data is required by European regulatory authorities considering IDM Pharma's marketing authorisation application for mifamurtide." Inpharma Weekly &NA;, no. 1646 (July 2008): 19. http://dx.doi.org/10.2165/00128413-200816460-00055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Venkatakrishnan, Karthik, William G. Kramer, Timothy W. Synold, Daniel B. Goodman, Evin Sides, and Cristina Oliva. "A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers." European Journal of Clinical Pharmacology 68, no. 10 (March 30, 2012): 1347–55. http://dx.doi.org/10.1007/s00228-012-1262-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Jimmy, Rincy, Sarahlouise White, and Karolina Lisy. "Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: A systematic review protocol." JBI Database of Systematic Reviews and Implementation Reports 12, no. 11 (December 11, 2014): 61. http://dx.doi.org/10.11124/jbisrir-2014-1774.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Anderson, P. M., P. Meyers, E. Kleinerman, K. Venkatakrishnan, D. P. Hughes, C. Herzog, W. Huh, et al. "Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments." Pediatric Blood & Cancer 61, no. 2 (August 31, 2013): 238–44. http://dx.doi.org/10.1002/pbc.24686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Brosa, Max, Xavier García del Muro, Jaume Mora, Alba Villacampa, Tamara Pozo-Rubio, Laia Cubells, and Carmen Montoto. "Orphan drugs revisited: cost–effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma." Expert Review of Pharmacoeconomics & Outcomes Research 15, no. 2 (October 29, 2014): 331–40. http://dx.doi.org/10.1586/14737167.2015.972378.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Lewis, I. J., C. Oliva, and Y. Liu. "Observational, Noninterventional Surveillance Study of Patients with High-Grade Osteosarcoma who are Candidates for Liposomal Mifamurtide Treatment." Annals of Oncology 23 (September 2012): ix490—ix491. http://dx.doi.org/10.1016/s0923-7534(20)34066-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Song, Hyun Jin, Eui-Kyung Lee, Jun Ah Lee, Hye-Lin Kim, and Kyoung Won Jang. "The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis." Tumor Biology 35, no. 9 (May 30, 2014): 8771–79. http://dx.doi.org/10.1007/s13277-014-2139-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Berisa, S., E. Lacalle, ME Carrasco, F. Marcotegui, S. Martínez, M. Gutiérrez, M. Castresana, M. Elviro, and E. Pellejero. "DGI-034 Evaluation of the Efficacy and Safety of Mifamurtide in Osteogenic Sarcoma Treatment in Paediatric Patients." European Journal of Hospital Pharmacy 20, Suppl 1 (March 2013): A107.2—A108. http://dx.doi.org/10.1136/ejhpharm-2013-000276.300.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Song, Hyun Jin, Jun Ah Lee, Euna Han, and Eui-Kyung Lee. "Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis." Tumor Biology 36, no. 9 (April 3, 2015): 6773–79. http://dx.doi.org/10.1007/s13277-015-3405-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Vargas-Romero, J. A., A. Figueroa-Rodriguez, J. Chiu-Ugalde, R. Sánchez-Kobashi, J. G. Gay-Molina, and J. C. López-Alvarenga. "Cost-Effectiveness and Cost-Utility Analysis of Mifamurtide Plus Combination Chemotherapy in Pediatric Patients with Osteosarcoma After Resection Surgery." Value in Health 16, no. 7 (November 2013): A686. http://dx.doi.org/10.1016/j.jval.2013.08.2035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Anderson, P., P. Meyers, E. Kleinerman, C. Oliva, and Y. Liu. "Mifamurtide (L-MTP-PE) for Metastatic and Recurrent Osteosarcoma (OS): Survival and Safety Profile from a Patient Access Study." Annals of Oncology 23 (September 2012): ix488. http://dx.doi.org/10.1016/s0923-7534(20)34055-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Venkatakrishnan, K., Y. Liu, D. Noe, J. Mertz, M. Mockler, T. Marbury, K. Farbakhsh, C. Oliva, and A. Milton. "593 Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Mifamurtide (L-MTP-PE) in Adult Volunteers with Mild and Moderate Hepatic Impairment (HI)." European Journal of Cancer 48 (November 2012): 182. http://dx.doi.org/10.1016/s0959-8049(12)72390-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Martinez Beltrán, Leila, Daniel Ozaeta Eidelman, and Natalia Lucía González Suárez. "Caracterización de los niños con osteosarcoma no metastásico quienes recibieron tratamiento con mifamurtida en dos instituciones de Bogotá (Colombia) entre 2014 y 2017." Universitas Médica 60, no. 4 (September 30, 2019): 1–8. http://dx.doi.org/10.11144/javeriana.umed60-4.oste.

Full text

Abstract:

Introducción: El osteosarcoma es el tumor óseo más frecuente en los niños. La supervivencia de los que no tienen metástasis al inicio del tratamiento no ha cambiado significativamente en la última década. Existen estudios que sugieren el beneficio del uso de nuevas moléculas como mifamurtida. Métodos: Se describieron las variables de interés en 8 pacientes menores de 18 años con osteosarcoma de alto grado no metastásico, que recibieron quimioterapia convencional y mifamurtida como adyuvante en 2 instituciones de Colombia entre 2014 y 2017. Resultados: La mayoría de los pacientes tenía afectación del fémur por osteosarcoma convencional. Todos se manejaron con quimioterapia pre y posquirúrgica. El 75 % de los pacientes fue llevado a salvamento de extremidad. En total se evaluaron 375 ciclos de mifamurtida a dosis de 2 mg/m2 de superficie corporal total. Se presentaron efectos adversos en 7 de los 375 ciclos administrados (1,87 %), en 4 de los 8 pacientes participantes en el estudio. Al finalizar el estudio, 6 de los 8 pacientes estaban vivos. Conclusiones: En los pacientes evaluados, el uso de mifamurtida fue bien tolerado; sin embargo, por el tipo de estudio, no se puede determinar si el uso de este medicamento tuvo impacto en la supervivencia.

APA, Harvard, Vancouver, ISO, and other styles

39

Venkatakrishnan, K., Y. Liu, D. Noe, J. Mertz, C. Oliva, and A. Milton. "582 Total and Non-liposome Associated (free) Muramyl Tripeptide-Phosphatidyl Ethanolamine (MTP-PE) Pharmacokinetics (PK) Following Intravenous (IV) Infusion of Liposomal Mifamurtide to Healthy Adults." European Journal of Cancer 48 (November 2012): 178. http://dx.doi.org/10.1016/s0959-8049(12)72379-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Emmerich, I. U. "Neue Arzneimittel für Kleintiere 2010." Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere 39, no. 06 (2011): 429–35. http://dx.doi.org/10.1055/s-0038-1623608.

Full text

Abstract:

ZusammenfassungIm Jahr 2010 kamen für Kleintiere weder Arzneimittel mit neuen Wirkstoffen noch Präparate mit einer Zulassungserweiterung hinsichtlich der Tierarten auf den deutschen Markt. Lediglich ein Tierarzneimittel mit einer interessanten neuen Darreichungsform, zwei Präparate in einer neuen Wirkstärke und ein aufgrund anderer Kriterien interessantes Präparat wurden 2010 eingeführt. Vorgestellt werden ferner neun im Jahr 2010 neu zugelassene Wirkstoffe für die Humanmedizin, die für die Tiermedizin interessant sein könnten (das Analgetikum Tapentadol, das Antiallergikum Bilastin, die Antiarrhythmika Dronedaron und Vernakalant, das Antihämorrhagikum Eltrombopag, das Broncholytikum Roflumilast, das Hormon Corifollitropin alfa, das Laxans Prucaloprid und das Zytostatikum Mifamurtid).

APA, Harvard, Vancouver, ISO, and other styles

41

"Mifamurtide." Reactions Weekly 1845, no. 1 (March 2021): 250. http://dx.doi.org/10.1007/s40278-021-92133-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Mifamurtide." Reactions Weekly 1717, no. 1 (September 2018): 193. http://dx.doi.org/10.1007/s40278-018-51263-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Mifamurtide." Reactions Weekly 1828, no. 1 (October 2020): 325. http://dx.doi.org/10.1007/s40278-020-85401-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Mifamurtide." Reactions Weekly 1665, no. 1 (August 2017): 189. http://dx.doi.org/10.1007/s40278-017-34758-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Mifamurtide." Reactions Weekly 1930, no. 1 (October 29, 2022): 352. http://dx.doi.org/10.1007/s40278-022-26615-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Review Editor, Business. "Junovan (mifamurtide)." PharmaDeals Review 2007, no. 80 (February 1, 2007). http://dx.doi.org/10.3833/pdr.v2007i80.384.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Not so NICE for mifamurtide." PharmacoEconomics & Outcomes News 608, no. 1 (July 2010): 3. http://dx.doi.org/10.2165/00151234-201006080-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Molecule of the month. Mifamurtide." Drug News & Perspectives 23, no. 3 (2010): 199. http://dx.doi.org/10.1358/dnp.2010.23.3.1492241.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Draft NICE guidance does not recommend mifamurtide." PharmacoEconomics & Outcomes News 614, no. 1 (October 2010): 9. http://dx.doi.org/10.2165/00151234-201006140-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"NICE news for mifamurtide, tocilizumab and ticagrelor." PharmacoEconomics & Outcomes News 641, no. 1 (November 2011): 10. http://dx.doi.org/10.2165/00151234-201106410-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!